ICE
Q1 2026 report
Revenue
0 m PLN
— YoY
Net income
-1.2 m PLN
— YoY
FCF
-2.97 m PLN
— YoY
CFO
-2.2 m PLN
— YoY
Summary
Investment thesis
- Zero długu odsetkowego, pozycja gotówki netto dodatnia (6,6 mln zł), ale gotówka spada o ok. 3 mln zł na kwartał
- Kluczowy katalizator kwartału: FDA 510(k) clearance dla CoolCryo (luty 2026) i zakończenie jego badania klinicznego (kwiecień 2026)
- AtriClamp otrzymał pozytywny feedback FDA na etapie pre-submission (maj 2026) — kolejny produkt zbliża się do fazy regulacyjnej
- Nierozstrzygnięty spór akcjonariacki o nową emisję akcji (seria O) może prowadzić do rozwodnienia lub zmiany struktury właścicielskiej
Read the full analysis
Financial data is open to everyone. The full analysis — management verdict, commentary, risks, and the full narrative — is available after you sign up or log in.
Financials
BETA
ICE · Q1 2026
| Metric | Q1 2026 | Q1 2025 | Δ YoY | Value type | Segment | Conf. |
|---|---|---|---|---|---|---|
| Revenue | 0 | — | — | reported | — | 1.00 |
| EBIT | -1.2 | — | — | reported | — | 1.00 |
| EBT | -1.21 | — | — | reported | — | 1.00 |
| Net income | -1.2 | — | — | reported | — | 1.00 |
| EPS (basic) (PLN) | -0.13 | — | — | reported | — | 1.00 |
| EPS (diluted) (PLN) | -0.13 | — | — | reported | — | 1.00 |
| D&A | 0.06 | — | — | reported | — | 1.00 |
| Shares (basic) (m units) | 9.28 | — | — | reported | — | 1.00 |
| Cash | 6.64 | — | — | reported | — | 1.00 |
| Total debt | 0 | — | — | reported | — | 1.00 |
| Net debt | -6.64 | — | — | derived | — | 1.00 |
| Equity | 86.91 | — | — | reported | — | 1.00 |
| Total assets | 90.68 | — | — | reported | — | 1.00 |
| Current assets | 7.08 | — | — | reported | — | 1.00 |
| Current liabilities | 0.58 | — | — | reported | — | 1.00 |
| Goodwill | 82.76 | — | — | reported | — | 0.90 |
| CFO | -2.2 | — | — | reported | — | 1.00 |
| CapEx | 0.77 | — | — | reported | — | 0.90 |
| FCF | -2.97 | — | — | derived | — | 0.90 |
| Current ratio | 12.27x | — | — | derived | — | 0.90 |
| Cash ratio | 11.51x | — | — | derived | — | 0.90 |
| EBIT growth (YoY) | -7.35% | — | — | derived | — | 0.90 |
| Net income growth (YoY) | -11.17% | — | — | derived | — | 0.90 |
Q1 2026 · Δ YoY
Revenue
0
—
0
—
- Q1 2025
- —
EBIT
-1.2
—
-1.2
—
- Q1 2025
- —
EBT
-1.21
—
-1.21
—
- Q1 2025
- —
Net income
-1.2
—
-1.2
—
- Q1 2025
- —
EPS (basic)
(PLN)
-0.13
—
-0.13
—
- Q1 2025
- —
EPS (diluted)
(PLN)
-0.13
—
-0.13
—
- Q1 2025
- —
D&A
0.06
—
0.06
—
- Q1 2025
- —
Shares (basic)
(m units)
9.28
—
9.28
—
- Q1 2025
- —
Cash
6.64
—
6.64
—
- Q1 2025
- —
Total debt
0
—
0
—
- Q1 2025
- —
Net debt
-6.64
—
-6.64
—
- Q1 2025
- —
Equity
86.91
—
86.91
—
- Q1 2025
- —
Total assets
90.68
—
90.68
—
- Q1 2025
- —
Current assets
7.08
—
7.08
—
- Q1 2025
- —
Current liabilities
0.58
—
0.58
—
- Q1 2025
- —
Goodwill
82.76
—
82.76
—
- Q1 2025
- —
CFO
-2.2
—
-2.2
—
- Q1 2025
- —
CapEx
0.77
—
0.77
—
- Q1 2025
- —
FCF
-2.97
—
-2.97
—
- Q1 2025
- —
Current ratio
12.27x
—
12.27x
—
- Q1 2025
- —
Cash ratio
11.51x
—
11.51x
—
- Q1 2025
- —
EBIT growth (YoY)
-7.35%
—
-7.35%
—
- Q1 2025
- —
Net income growth (YoY)
-11.17%
—
-11.17%
—
- Q1 2025
- —